Used Bioprocess Gear Hot
- Recent auction listings show strong appetite for pre‑owned bioprocess equipment from brands like Pall and Sartorius. (x.com) - Specific inventory includes 200–2,000L single‑use and stainless bioreactors plus TFF skids previously used at Emergent Bio. (x.com) - The activity aligns with broader CGT automation and capacity shifts as manufacturers balance new builds with second‑hand buys. (x.com) (x.com)
Used bioprocess gear is moving fast through liquidation channels as drug manufacturers look for cheaper ways to add capacity. (auctions.fedequip.com) A late-April 2026 auction tied to Emergent BioSolutions in Baltimore listed unused Pall single-use mixers and bioreactors in 200-, 650-, 1,500-, and 2,000-liter sizes, plus unused Sartorius 200-liter wave bioreactors. (auctions.fedequip.com) The same sale included a Sartorius 1-inch tangential flow filtration skid, GE AKTA purification systems, Millipore Mobius mix systems, Watson-Marlow pumps, and Sartorius Biostat controls. Tangential flow filtration is a membrane-based step used to concentrate or clean biologic products. (hgpauction.com) Federal Equipment said the Emergent auction ran online on April 22-23, 2026, with Heritage Global Partners, and described the assets as unused or late-model biopharma processing equipment. (auctions.fedequip.com) (industrialauctionnews.com) The draw is simple: new bioreactors and filtration systems can take months to source and install, while auction lots can be bought and moved immediately if a plant has the space and validation plan. Industrial Auction News said the Baltimore sale offered “production-ready assets” without the lead times attached to new equipment. (industrialauctionnews.com) That buying pattern fits a broader manufacturing shift in cell and gene therapy, where companies are trying to cut cost and labor with more automation and standardized equipment. BioProcess International reported in March 2026 that automation is being pushed as a way to improve efficiency, quality, and access in cell and gene therapy production. (bioprocessintl.com) Researchers have been making the same case in the technical literature. A 2025 review in *Trends in Biotechnology* said developers are pursuing automation to increase throughput and contain cell therapy costs, while a 2025 *Frontiers* paper said manufacturing complexity and limited fit-for-purpose tools still constrain scale-up. (sciencedirect.com) (frontiersin.org) Emergent’s Baltimore assets have been coming to market in multiple tranches, not a single one-off sale. Heritage Global Partners posted earlier 2026 liquidation rounds with Pall 2,000-liter mixers, Xcellerex bioreactors, Parker and Sartorius filtration skids, and Sartorius 2,000-liter wave bioreactors. (hgpauction.com 1) (hgpauction.com 2) A second-hand channel for branded systems from Pall, Sartorius, Cytiva, Millipore, and Thermo Fisher also already exists outside auctions. Marketplace listings from Surplus Solutions, Machinio, and LabX show steady resale inventory for the same categories of bioprocess equipment. (ssllc.com) (machinio.com) (labx.com) For buyers, the appeal is not just price. The April Baltimore catalogs show something harder to find in a tight market: multiple matching units from the same site, in the same process families, available at once. (auctions.fedequip.com) (hgpauction.com)
